Patents by Inventor David A. Degoey

David A. Degoey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-Viral Compounds
    Publication number: 20230285378
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: September 9, 2022
    Publication date: September 14, 2023
    Applicant: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Warren M. Kati, Tammie K. Jinkerson, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20220213092
    Abstract: The present invention provides for compounds of formula (I) wherein A, R1, R2, R4, W, m, and n have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL and/or SLL.
    Type: Application
    Filed: December 16, 2021
    Publication date: July 7, 2022
    Inventors: David A. DeGoey, Felix DeAnda, Jr., Amanda W. Dombrowski, Igor Dubovyk, Stephen N. Greszler, Dimitri Khrakovsky, Chih-Hung Lee, James N. Newton, Elizabeth L. Noey, Akinori Okano, Kevin B. Sippy, Andrew J. Souers, Longcheng Wang, Noel S. Wilson, Jeffery A. Zablocki
  • Compositions and Methods for Treating HCV Infection
    Publication number: 20190358214
    Abstract: The present invention features compositions and methods for the treatment of HCV infection. In one embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) Compound 2a or a pharmaceutically acceptable salt thereof. In another embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) a prodrug of Compound 2a (e.g., one of Compounds 2b-2k or Examples 3-1 to 3-10) or a pharmaceutically acceptable salt of said prodrug.
    Type: Application
    Filed: November 13, 2017
    Publication date: November 28, 2019
    Applicant: AbbVie Inc.
    Inventors: Brian Brown, Hui-Ju Chen, David DeGoey, Geoff Halvorsen, John Hartung, Howard R. Heyman, Nathan Ide, Dale Kempf, Allen C. Krueger, Tao Li, Tongmei Li, Steven R. Martinez, Christopher C. Marvin, John T. Randolph, Eric Voight, Rolf Wagner, Jaclyn Chau
  • TERTIARY AMIDES AND METHOD OF USE
    Publication number: 20190119200
    Abstract: Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: April 6, 2017
    Publication date: April 25, 2019
    Inventors: Lawrence A. Black, William H. Bunnelle, Da Chen, Bruce Clapham, David A. Degoey, Xiangjun Deng, Liqiang Fu, Lisa A. Hazelwood, Linglong Kong, Qingyu Lang, Chih-Hung Lee, Mingfeng Li, Greta L. Lundgaard, Meena V. Patel, Ruihong Tao, Lin Zhang, Qingwei Zhang, Qiangang Zheng, Wei Zhu
  • Anti-Viral Compounds
    Publication number: 20190015402
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: July 23, 2018
    Publication date: January 17, 2019
    Applicant: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE
    Publication number: 20180334435
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: April 13, 2018
    Publication date: November 22, 2018
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • Anti-viral compounds
    Patent number: 10053474
    Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 21, 2018
    Assignee: AbbVie Inc.
    Inventors: Jaclyn Chau, Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight, Brian S. Brown, Steven R. Martinez, Anurupa Shrestha, Howard R. Heyman
  • Anti-viral compounds
    Patent number: 10039754
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: August 7, 2018
    Assignee: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • Anti-viral compounds
    Patent number: 10028937
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: July 24, 2018
    Assignee: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
    Patent number: 9969693
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: May 15, 2018
    Assignee: AbbVie Inc.
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • Anti-Viral Compounds
    Publication number: 20180022763
    Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: May 5, 2017
    Publication date: January 25, 2018
    Applicant: AbbVie Inc.
    Inventors: Jaclyn Chau, Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight, Brian S. Brown, Steven R. Martinez, Anurupa Shrestha, Howard R. Heyman
  • Indazole ureas and method of use
    Patent number: 9783527
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, R1 and R2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: October 10, 2017
    Assignee: AbbVie Inc.
    Inventors: Jerome F. Daanen, David A. DeGoey, Jennifer M. Frost, John R. Koenig, Steve Latshaw, Mark Matulenko, Marc Scanio, Lei Shi, William H. Bunnelle
  • 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE
    Publication number: 20170226062
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: August 17, 2016
    Publication date: August 10, 2017
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • (Indazol-4-yl) hexahydropyrrolopyrrolones and methods of use
    Patent number: 9682985
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein GAr, L1, Z1 and Z2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: June 20, 2017
    Assignee: AbbVie Inc.
    Inventors: Jerome Daanen, David DeGoey, Jennifer M. Frost, Tammie Jinkerson, Steve Latshaw, Lei Shi
  • Anti-viral compounds
    Patent number: 9676797
    Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: June 13, 2017
    Assignee: AbbVie Inc.
    Inventors: Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Jaclyn Chau, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight
  • Anti-Viral Compounds
    Publication number: 20170157105
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: February 16, 2017
    Publication date: June 8, 2017
    Applicant: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • Anti-Viral Compounds
    Publication number: 20170157104
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: February 13, 2017
    Publication date: June 8, 2017
    Applicant: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean-Christophe C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • Antiviral compounds and uses thereof
    Patent number: 9637478
    Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: May 2, 2017
    Assignee: AbbVie Inc.
    Inventors: David A. Betebenner, John K. Pratt, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Douglas K. Hutchinson, Warren M. Kati, Allan C. Krueger, Kenton L. Longenecker, Clarence J. Maring, John T. Randolph, Todd W. Rockway, Michael D. Tufano, Rolf Wagner, Dachun Liu
  • Anti-viral compounds
    Patent number: 9586978
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 7, 2017
    Assignee: AbbVie Inc.
    Inventors: Mary E. Bellizzi, David A. Betebenner, Jean C. Califano, William A. Carroll, Daniel D. Caspi, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Yi Gao, Charles W. Hutchins, Douglas K. Hutchinson, Tammie K. Jinkerson, Warren M. Kati, Ryan G. Keddy, Allan C. Krueger, Wenke Li, Dachun Liu, Clarence J. Maring, Mark A. Matulenko, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, John K. Pratt, John T. Randolph, Todd W. Rockway, Kathy Sarris, Michael D. Tufano, Seble H. Wagaw, Rolf Wagner, Kevin R. Woller
  • Anti-Viral Compounds
    Publication number: 20170057981
    Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 2, 2017
    Applicant: AbbVie Inc.
    Inventors: Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Jaclyn Chau, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight